Tumor organoids in translational cancer research: Models for personalized therapy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Translational Medicine

ISSN

2220-6132

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Transl Med. Feb 12, 2026; 12(1): 113050
Published online Feb 12, 2026. doi: 10.5528/wjtm.v12.i1.113050

Table 1 Tumor organoid applications in drug screening

Cancer type	Drug tested	Organoid response	Clinical relevance
Colorectal	5-fluorouracil	Organoids responded well, mimicking patient responses	High
Ovarian	Platinum-based chemo	Identified platinum-resistant populations	High
Lung	EGFR inhibitors	EGFR-mutant organoids sensitive to inhibitors	Moderate

Citation: Agrawal H, Tanwar H, Gupta N. Tumor organoids in translational cancer research: Models for personalized therapy. World J Transl Med 2026; 12(1): 113050
URL: https://www.wjgnet.com/2220-6132/full/v12/i1/113050.htm
DOI: https://dx.doi.org/10.5528/wjtm.v12.i1.113050

Agrawal H, Tanwar H, Gupta N. Tumor organoids in translational cancer research: Models for personalized therapy. World J Transl Med 2026; 12(1): 113050 [DOI: 10.5528/wjtm.v12.i1.113050]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.